The US Food and Drug Administration (FDA) has granted fast track designation to Pyxis Oncology’s antibody-drug conjugate (ADC ...

Receiving Fast Track designation for PYX-201 from the FDA marks a significant milestone for Pyxis Oncology, recognizing our potential to address the significant medical need in R/M HNSCC. This ...

Pyxis Oncology (PYXS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of ...

(RTTNews) - Pyxis Oncology, Inc. (PYXS) Wednesday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PYX-201, the company's drug candidate for the ...

Two PYX-201 trials are now actively recruiting and are designed to evaluate PYX-201 as monotherapy in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC ...

Shares of Pyxis Oncology (NASDAQ:PYXS) traded higher in the premarket on Wednesday after the U.S. FDA issued its Fast Track ...

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) have received an average recommendation of “Moderate Buy” from ...

For example, biotech and mining... - Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA ...

PYX-201 has gained FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

PYX-201 is a first-in-concept antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix ...